The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "biosimilars"

Search results for: biosimilars

UHC Updates Rituximab Policy to Require Use of Biosimilars

October 19, 2020 • By From the College

As of Oct. 1, UnitedHealthcare (UHC) requires that patients fail to respond to both FDA-approved rituximab biosimilars prior to receiving approval for rituximab. Exception: Rituximab-pvvr (Ruxience) is not FDA approved for rheumatoid arthritis.... [Read More]

Filed Under: Billing/Coding Tagged With: biosimilar substitution, non-medical switching, prior authorization, rituximab, rituximab-abbs, UnitedHealthCare (UHC)

Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

June 15, 2020 • By Bryn Nelson, PhD

Medicalwriters/Science Source

As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists… [Read More]

Filed Under: Biologics & Biosimilars, Research Reviews Tagged With: Arthritis & Rheumatology, drug costs, infliximab

British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars

May 29, 2019 • By Allison Martell & Allison Lampert

TORONTO/MONTREAL (Reuters)—The Canadian province of British Columbia said on May 28 that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million) over three years. The new policy from the province’s PharmaCare program targets Johnson & Johnson’s… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biologics, Biologics & Biosimilars, Biosimilars, Canada

Biosimilars: How Do They Affect Patient Care & Safety?

March 19, 2019 • By Lara C. Pullen, PhD

CHICAGO—“We have got to get over this hump. We have got to try new stuff,” said Jacqueline M. Fritz, RN, MSN, CNS, to the audience gathered on the final day of the 2018 ACR/ARHP Annual Meeting, referring to the subject of biosimilars. Ms. Fritz, the owner and coordinator of education at the Medical Advancement Center… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates, Meeting Reports Tagged With: 2018 ACR/ARHP Annual Meeting, adalimumab-atto, etanercept-szzs, filgrastim-sndz, infliximab-abda, infliximab-dyyb

The Science Behind Biosimilars

February 27, 2018 • By Arthritis & Rheumatology

Although six biosimilar agents have now been approved by the U.S. Food & Drug Administration for use in rheumatology, scientific, clinical, economic and prescribing questions about the use of biosimilars abound. In fact, at the 2017 ACR/ARHP Annual Meeting in San Diego, Joseph Huffstutter, MD, a rheumatologist in private practice in Chattanooga, Tenn., said that… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Arthritis & Rheumatology, Biologics & Biosimilars, Biosimilars

Health Plans Enact Coverage Policies for Remicade & Infliximab Biosimilars

February 16, 2018 • By From the College

Several major health plans have recently enacted policies regarding coverage status for Remicade (infliximab) and its biosimilars, Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda). Most of these plans are limiting coverage for the biosimilar products to very specific circumstances. Some have also begun denying claims for biosimilars and instructing patients to switch to Remicade. The plans implementing… [Read More]

Filed Under: Biologics & Biosimilars, From the College, Practice Management Tagged With: Blue Cross, Blue Shield, Cigna Corp., coverage status policies, Humana Inc., INFLECTRA (infliximab-dyyb), REMICADE (infliximab), Renflexis (infliximab-abda), United Healthcare

Biosimilars: Still Waiting for Promise to Materialize

January 17, 2018 • By Larry Beresford

During the 2017 ACR/ARHP Annual Meeting, advances in biosimilar treatments were abuzz. However, many speakers noted that the presence of biosimilars on the market has not yet resulted in greater access to treatment and lower drug pricing in the U.S…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates, Meeting Reports Tagged With: 2017 ACR/ARHP Annual Meeting, ACR/ARHP Annual Meeting, Biologics & Biosimilars, biosimilar, drug pricing, Drug Updates, interchangeability

Biosimilars Great Debate: To Switch or Not?

November 17, 2017 • By Susan Bernstein

SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked… [Read More]

Filed Under: Biologics & Biosimilars, Education & Training, Meeting Reports Tagged With: 2017 ACR/ARHP Annual Meeting’s Great Debate, Biologics, biosimilar, Jonathan Kay, Rheumatic Disease, Roy Fleischmann

CMS Implements Part B Modifiers for Biosimilars

September 20, 2017 • By From the College

With the advent of biosimilars to the marketplace, the Centers for Medicare and Medicaid Services (CMS) now requires modifiers to identify the manufacturer of a biosimilar/biological product on Part B claims. Modifiers were put in place to provide the CMS with the necessary data needed to track claims payments, as well as the ability to… [Read More]

Filed Under: Biologics & Biosimilars, From the College Tagged With: Biosimilars, Centers for Medicare and Medicaid Services (CMS), Inflectra, Part B modifiers for biosimilars, Renflexis

2 Biosimilars Make Their Way Toward the European Market

July 17, 2017 • By Michele B. Kaufman, PharmD, BCGP

Two biosimilar treatments, Rixathon and Imraldi, are moving closer to market release in Europe for the treatment of rheumatic and other diseases…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, Biosimilars, European Medicines Agency, Psoriasis, rituximab, Rixathon

  • 1
  • 2
  • 3
  • …
  • 24
  • Next Page »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.